Small Cap Feast
Small Cap Feast – 04 October 2019
Dish of the Day:
No Joiners Today
No Joiners Today
Off the Menu:
No Leavers Today
No Leavers Today
What’s Cooking in the IPO Kitchen?
Main Market Standard
Kaspi.kz, the largest Payments, Marketplace and Fintech Ecosystem in Kazakhstan with a leading market share in each of its key products and services. GDR offering expected Oct 2019. In the first half of 2019, the Company generated total revenue of KZT226,862m (U.S. $598m), up 34% and net income of KZT77,001m (U.S. $203m), up 54%.
Main Market premium
Registration document approved for Helios Towers. The Group provides essential network services, flexible infrastructure solutions and reliable power supply to mobile network operators in five African growth economies. Revenue increased 7 per cent. year-on-year to US$191m (H1 2018: US$178m), with Adjusted EBITDA up 15 per cent. year-on-year at US$99m (H1 2018: US$86m) for the six months ended 30 June 2019. Pricing rumoured at 115p to 145p implying valuation of up to $1.8bn
Treatt (TET.L) 405p £239
“The manufacturer and supplier of innovative ingredient solutions for the flavour, fragrance, beverage and consumer product industries today publishes a trading update for the year ended 30 September 2019.
The Board is pleased to c o n f i r m t h a t , notwithstanding a very significant fall in certain key citrus raw material prices, and some foreign exchange headwinds, the Group has performed well in the second half of the f i n a n c i a l y e a r . Consequently, the Board expects to report profit before tax and exceptional items for the year ended 30 September 2019 in line with its expectations.
Revenue for the year is e x p e c t e d t o b e approximately £112.7m, an increase of 1% (or decrease of 2% in constant currency) compared with the prior year. As reported in May 2019, revenue for the year has been impacted by a substantial fall in citrus raw material input prices, with orange oil (which represents approximately 33% of Group revenue) prices falling by more than 50% over the year and lemon oil prices also seeing s u b s t a n t i a l p r i c e weakness. “
Columbus Energy (CERP.L) 4.2p £35
The oil and gas producer and explorer with operations onshore Trinidad, is pleased to announce the signature of a Production Sharing Contract with Staatsolie Maatschappij Suriname N.V (“Staatsolie”) for the Weg Naar Zee Block, onshore Suriname.
· Onshore block with a discovered resource of 24mmbbl (STOIIP) in a proven hydrocarbon province.
· Large block ( 9 0 0 k m ² ) w i t h exploration potential.
· No signature bonus or upfront consideration.
· Company can control timing of appraisal/ development work. Phase 1 Exploration Period (3 years) consists of G&G studies and 2 Extended Well Tests.
· Suitable for application of Enhanced Oil Recovery techniques used by Columbus in Trinidad.
· Complimentary to existing operations and onstrategy.
Beowulf M i n i n g (BEM.L) 6.375p £37.5m
The update on its application for an Exploitation Concession for the Kallak North iron ore project (“Kallak”).
CEO’s Letter to the Minister of Enterprise and Innovation
The Company has received a response to the letter sent by the CEO to Mr Ibrahim Baylan, Minister for Enterprise and Innovation, The Government of Sweden. The Minister has explained that since the CEO’s request for a meeting “concerns a f o r t h c o m i n g Government decision – a dossier that is currently under preparation”, the Government is unable to meet or comment with regard to its “ongoing review”.
“The legal analysis is unequivocal, that the Company has robustly argued its case for a Concession to be awarded. “
Angle (AGL.L) 78.5p £135.6m
The Queen Mary University of London (QMUL) European patent covering the measurement of the n u m b e r o f megakaryocytes in a patient blood sample as an assessment of the prognosis for prostate cancer has been granted.
ANGLE has an option agreement, exercisable up until 14 June 2021, with QMUL for an exclusive worldwide licence over the use of its megakaryocyte intellectual property. The grant of the European patent protects the Company’s ability to offer a megakaryocyte-based test in Europe. Similar patents are being pursued in the United States and certain other major territories.
QMUL published research in Clinical Cancer Research in 2017 using ANGLE’s Parsortix® system showing that the number of megakaryocyte cells in the blood of prostate cancer patients correlates closely with increased patient survival. This was the first time the presence of these cells in patient blood has been shown to be connected to cancer prognosis and to date no competing system has published success in this area.
Sureserve (SUR.L) 29p £46m
The Compliance and Energy Support Services Group, announced an FY Sep 19 trading update
The demand for the Group’s services continue to be strong, on the back of its reputation for the delivery of quality services and market leading positions in the highly regulated public sector gas maintenance and energy management sectors.
Both operational and financial performances have been strong in the second half of the year and the Board is pleased to confirm that the pre-tax profits for the year just ended will meet management’s expectations.
Michael McMahon, the Chief Operating Officer, has advised that he has decided to resign for personal reasons and Bob Holt will fulfil Michael’s role during this interim period whilst the Board structure is reviewed.
SRT Marine (SRT.L) 39.6p £61.3m
“SRT, the global provider of maritime surveillance, monitoring and management systems, is pleased to provide a trading update for the six months trading period ended 30th September 2019.
Revenues during the first half increased year on year by 10% from £3.2m to £3.5m, generating a forecast half year loss before tax of £1.5m compared to £1.3m for the same period last y e a r . A s a t 30th September 2019, the Company had £1.7m of cash. During the period, and as expected, the Company has received all expected cash payments in respect of its systems business f r o m p r e v i o u s l y completed milestones and purchased and paid for significant quantities of equipment required to complete scheduled p r o j e c t d e l i v e r y milestones during the second half of the year. “
Coro Energy (CORO.L) 2.925p £23.1m
“The Southeast Asian focused upstream oil and gas company, is pleased to provide an operational update in relation to the drilling campaign in the Duyung Production Sharing Contract (“PSC”) in the West Natuna basin, offshore Indonesia, in which Coro holds a 15% interest. As previously reported, the drilling rig Asian Endeavour 1 was mobilised from Singapore on 24th September 2019 and has been on location since Monday 30th September. P r e – l o a d i n g o f equipment and supplies for the two well programme has now completed and drilling of the Tambak-2 well has c o m m e n c e d . ” A n independent review by Gaffney Cline & Associates ascribed gross 2C resources of 276 Bcf (48.78 MMboe) of recoverable dry gas in the Mako field with gross 3C resources of 392 Bcf (69.3 MMboe) representing additional field upside
Audioboom (BOOM.L) 157.55p £22.06
The leading global podcast company, announced two new shows at the Interactive Advertising Bureau’s first Podcast Upfronts event on 3 October 2019.
The Podcast Upfronts is the newest addition to the IAB’s Digital Upfronts week, which brings together major brands within the podcasting industry to inform, inspire, and educate the advertising community.
Audioboom’s Senior Vice President of Global Sales & Development, Thomas Mancusi and UK Head of Content, Mike Newman represented Audioboom at Shoreditch Town Hall where the new shows were announced.
Big Sofa Tech (BST.L) 4.35p £8.1m
The international video analytics provider to the c o n s u m e r i n s i g h t industry, announces a new agreement with two divisions of Ipsos for an annu al mini mu m purchase commitment totalling $300,000.
This initial 12-month m i n i m u m p u r c h a s e commitment will grant the Ipsos companies access to Big Sofa Technologies’ proprietary platform and core technical services on a fully integrated basis.
Blackbird (BIRD.L) 12.4p £36.6m
The developer and seller of the market-leading cloud video platform Blackbird, announces that Jim Irving, a non-executive director of the Company, will step down from the Board on 22 November 2019 to focus on other business interests.
0203 764 2344
*A corporate client of Hybridan LLP
This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.
The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.
The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).
Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.
This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.
In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.
Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.
Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.
Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.
This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.
MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.
If you would like to unsubscribe, please email email@example.com with “unsubscribe me”.